In recent years, there has been some provocative evidence that gadolinium, the most widely used contrast agent for MRI studies has a tendency to accumulate in the brain. This fact has been confirmed by multiple major studies but there is still little direct proof of ill effects. It turns out, there have been some interesting insights regarding these concerns, but what has recently burst onto the scene is a new alternative to gadolinium altogether. Scientists have found a way to take advantage of a unique property of cancerous tumors, and now propose a novel contrast agent, D-glucose, more commonly known as dextrose. With this new contrast, healthcare professionals can potentially circumvent gadolinium for investigating brain tumors.